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Unprovoked Seizures and Myoclonus
in Patients with Alzheimer's Disease
MARCIA L. MORRIS*

ABSTRACT - Althou?h anecdotal references commonly presume that seizures eventually occur in patients
affected with dementia of the Alzheimer type (OAT), no previous American study has documented
the rate of new onset, unprovoked seizures in OAT patients. There are few documented cases of the occurrence
of myo_clonus in autopsy-proven OAT. In a series of 83 autopsy-proven OAT cases, medical records were
scrutinized for the presence of any seizure or myoclonic activity. Final evaluations were made by a neurologist.
Of the 83 cases, 8 had experienced one or more unprovoked seizures after the onset of OAT. Based on
age-specific incide_nce rates from a population study of Rochester, Minnesota, the expected number was 0.80
Cp<.Ol). Eight patients developed myoclonus during the dementing illness. (No appropriate general population study exists that would make comparison of rates of new onset myoclonus possible.) There was no overlap
?et:-'~en tho~e who developed myoclonus and those who developed seizures. These data suggest that
m?!Vlduals with OAT have a tenfold greater risk of developing seizures than an age-matched control, but that
seizures cannot be considered a universal sign of OAT. Whether this increase in risk is uniform or whether
seizures or myoclonus define unique subgroups of OAT types remains to be explored.
'

Introduction
Primary senile dementias have only come to be recognized
as true disease states since 1956 when data from the National
Institute of Mental Health (NIMH) Human Aging Study challenged the notion that "senility" was an inevitable result of
normal aging ( 1,2). Neuropathological studies during the past
15 years have now established that senile dementia of the
Alzheimer type (SDAT) accounts for over 60% of the cases of
primary dementia occurring in people over 65 (3). Alzheimer's Disease is clinically and pathologically the same disease
except that, by historic and arbitrary definition, onset occurs
before age 65 (2,3,4). Unless specifically stated, Dementia of
the Alzheimer's Type (DAT) will be used here to indicate all
affected persons regardless of the age of initial onset.
DAT victims progress from barely perceptible lapses in
recent memory to increasingly handicapping and dehumanizing losses in judgment, emotionality, and physical function.
This inevitably lethal decline is without remission and usually
lasts for8 to lOyears after onset of symptoms. There is no cure,
no effective treatment, and no practical, positive, pre-mortem
diagnosis (4).
Coupling these facts with current and projected numbers of
cases, it is understandable that scientific interest in Alzheimer's Disease is rapidly increasing. The proportion of older
persons in the general population will continue to climb
rapidly well into the 21st century, and it is this numerically
increasing group that is at risk for DAT (Figure 1) (5). While
there is as yet no definitive study of the prevalence or incidence of DAT (6), it is estimated that DAT currently affects
about 1.5 million people in the U.S. alone and causes or
contributes to the death of 100 thousand older Americans per
year (1,7).

The primary rationale for study of seizures in patients with
DAT is two-fold. First, there is a clinical need for correct
information. Scientitk literature and neurology textbooks
commonly disagree on seizure rates. Some conclude that
seizures are rare or unlikely. Meanwhile inferences are commonly made, both orally and in print, among both laypersons
and clinical professionals, that seizures are so common in
patients with Alzheimer's Disease that they may in fact be
inevitable. Because many DAT patients and their loved ones
find this prognosis especially anxiety provoking, any exaggeration of risk should not be viewed as harmless misinformation. Yet no previous American study has documented the rate
of new onset, otherwise unprovoked seizures in patients
affected with DAT (8). However, a Finish study of clinical
findings in dementia noted that 6 out of 71 non-autopsy
proven DAT cases had seizures (9). There are documented
cases of the occurrence of myoclonus in autopsy proven DAT,
but no appropriate age specific control rates are available for
comparison (10,11).
The second rationale involves basic scientific inquiry.
Because secondary cases ofDAT are present in about 33% of
the families located through one affected person (proband),
both familial and sporadic cases appear to occur. The percentage of familial cases rises to about 43% if only those probands
who were affected before the age of 65 are considered (12).
Any marker such as seizures or myoclonus occurring in one
DAT group but not in another would be of interest, since such
differences might signal different underlying biochemical or
physiological changes.

Methods
Medical records, death certificates, and family interviews
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th e onset of OAT. Three of these experienced single episodes,
while 5 had recurrent seizures. Based on age-specific incidence rates for combined single and multiple seizures from a
population study of Rochester, Minnesota, the expected total
is 0.80 (significant, p<. 01 , Poisson) ( 13 ). Another 2 probands
experienced seizures before OAT onset, both having had
seizures during childhood. This result is not significantly
different from the .65 expected. A total of 8 probands experienced myoclonus after the onset of OAT. No cases of myoclonus were recorded prior to OAT. Appropriate age-specific
incidence rates for comparison are unavailable for myoclonus. There is no overlap between those probands who experienced myoclonus and those who experienced seizures.
The mean age ofOATonset was 71.3 for all 83 probands, 11
of whom were determined to have had an onset prior to age
65 (Table 1). Of the 11 with OAT onset prior to age 65, one had
seizures and another had myoclon us (Table 2). The mean age
of OAT onset was slightly lower in those who subsequently
developed seizures (69 years) than the mean age for those
who developed myoclonus (73.5 years). The mean age of
seizure onset in those patients with OAT was 75.6 years, while
the mean age for myoclonus onset was 79.5 years. The mean
duration of illness in the OAT cases who developed seizures,
9.1 years, was slightly longer than those who developed myoclonus, 6.8 years; or neither, 8.3 years. The mean survivorship
following onset of myoclonus was 1.1 years (Table 3 ).
Table 1. Age distributi on of Alzheimer's onset.
Age Interval (Years)

Number of Persons

50-59
60-64
65-69
70-79
80-89
90-99

2
9
22
36
14
0

Figure 1. Estimated number of Alzheimer's Disease cases, U.S.,
1900-2030.

were scrutinized for an unselected series of83 probands with
autopsy proven OAT who died in Minnesota state hospitals
between 1952 and 1972. Any diagnosis of, or reference to,
seizures or myoclonic activity were reviewed and classified by
a neurologist. All of the seizure activity observed was of a
generalized tonic-clonic nature, while a diagnosis of myoclonus was made for cases exhibiting characteristic myoclonic
shocklike or jerking movements involving only a subset of
muscles.
Using death and medical records as a source of data, like
most archival types of research, can be criticized on several
grounds: the amount of information available about the proband varies, the cause of death listed may depend on the
extent to which the person was studied medically before
death, on the certifying physician's famili arity with the patient,
and on whether or not an autospy was done; diagnostic
labeling and reporting can vary from one area to another in
medical practices.
These shortcomings have been largely ameliorated in this
study. The probands were all patients who had died in one of
three Minnesota state hospitals during a discrete time period,
which maximizes the homogeneity of the assessment and
reporting methods used by the physicians and support personnel. Moreover, all 83 probands were autopsied, and full
autopsy reports were available and studied. All medical
information dating from the time of the probands' admission
to the state hospitals until death, including reports of previous
medical history, was available. This information was further
amplified during field interviews with the probands' family
members.

Results
Among the 83 OAT probands, 8 (9.6%) had seizures after
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Total

83

Table 2. Myoclonus and seizures by age of Alzheimer's onset.
Number of Persons in Interval
Myoclonus
Seizures

Age Interval (Years)

50-59 .
60-64
65-69
70-74
75-79
80-84
85-89
90-94

0

Total

0

1

1

2

0

1

2

1

3

1
2

1
1

0

0

8

8

Table 3. Age at onset of DAT seizures, and myoclonus.

Mean Age
at DAT Onset

Mean Age
at Onset of
Seizures or
Myoclonus

Mean Age
at Death

(Std . Dev.)

(Std. Dev.)

(Std. Dev.)

75 .6
( 8.0)
79.5
( 7.6)

79.6
( 6.0)
78.1
( 8.1)
80.3
( 7.7)

DAT alone

71.3
( 6.7)

DAT plus
seizures

69.0
( 8.6)
73.5
( 9.3)

DAT plus
myoclonus

9

Discussion

.

These data suggest that individuals with OAT have a tenfold
greater risk of developing seizures than an age-matched control, but that seizures cannot be considered a universal sign of
DAT. Although the lack of an appropriate control study makes
the absolute determination of the increased risk for myoclonus impossible, the observed 9.6% who developed myoclonus is probably a significant increase over an expected
number. It is not clear whether these increases in risk are
uniform or whether seizures or myoclonus occur only in
unique subgroups ofDAT. In spite ofthe lowered OAT mean
age of onset in prob~mds who developed seizures, the one
incidence each of myoclonus and seizures in the group with
DAT onset prior to age 65 tends to make this criteria an
unlikely condition upon which to separate subgroups. Of
more interest for continued research may be the lack of
overlap between those probands who experienced myoclonus and those who experienced seizures.
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